Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There is an increasing body of genetic and biochemical evidence that points toward lysosomal dysfunction as a risk factor for developing age-related neurodegenerative disorders, including Parkinson’s disease (PD).

The highest genetic risk factor for developing PD is loss-of-function mutations in the GBA gene, which encodes the lysosomal hydrolase acid beta-glucocerebrosidase, the enzyme deficient in the lysosomal storage disorder, Gaucher Disease. The exact mechanism(s) leading to increased risk of PD in Gaucher patients and GBA1 mutation carriers is unclear; however a generally well accepted concept in the PD community is that a critical relationship exists between endosomal-lysosomal dysfunction, an imbalance in glycosphingolipids (GSL), and the development of PD.

Developing therapies for the treatment of rare lysosomal storage disorders (LSD) and neurologic diseases is currently aligned with the overall strategic mission of the Rare Disease Research Unit (RDRU) at Pfizer.

Working with the Medical Sciences Business Partnerships team, Professor Fran Platt was able to secure funding for two years in the first instance to better understand endosomal-lysosomal dysfunction and the role of GSL in PD, potentially leading to identification of novel therapeutic targets for the treatment of this devastating disease.

Fran commented, "We are delighted to have this opportunity to work in partnership with Pfizer on the validation of a potential new therapeutic target for PD that we recently identified”.

Work on this project started in July, with the return of Fran’s lab to the Department of Pharmacology.

Similar stories

International collaboration by Potter group uncovers vital element in regulation of Na⁺/K⁺- ATPase-α1

Department

An international collaboration of the Potter Group with Solomon Snyder’s Group in the USA and with Chinese and German colleagues has uncovered the myo-inositol polyphosphate pyrophosphate 5-InsP7 as a regulator of the Na⁺/K⁺- ATPase-α1

Professor Angela Russell receives 2021 Harrington UK Rare Disease Scholar Award

Department Russell Group

Angela Russell, Professor of Medicinal Chemistry in the Oxford Departments of Pharmacology and Chemistry, has been announced as one of the five recipients of the inaugural UK Rare Disease Scholar Award, presented by the Harrington Discovery Institute (HDI).

Professor Fran Platt appointed as new Head of Department of Pharmacology

Department

Professor Fran Platt has been appointed as the new Head of Department for Pharmacology at the University of Oxford. Fran took up her new post with effect from 1 June 2020 and will serve for an initial period of five years.

The Department mourns the loss of three greats in neuropharmacology

Department

This summer three of the world’s most distinguished neurochemists died; each was a member of the Department during their outstanding scientific careers.

New Galione group paper explores the role for early Ca2+ signals in phagocytosis

Department

The Galione Lab has a paper published in The EMBO Journal showing that local Ca2+‐nanodomains formed by two‐pore channels (TPCs) on endo-lysosomes are shown to drive phagocytosis in macrophages. Moreover, different endo-lysosomal Ca2+ channels do different jobs at phagocytosis (extreme compartmentation).